To Evaluate the Safety and Performance of the AMS ActivHeal Silicone Foam and the ActivHeal Silicone Foam Lite Dressing.

Advanced Medical Solutions Ltd.160 enrolled

Overview

To demonstrate the safety and performance of both AMS ActivHeal Silicone Foam and AMS ActivHeal Silicone Foam Lite dressings to both the patient and clinician in managing both chronic and acute wounds.

This PMCF study has been set up to investigate and assess residual risks in relation to the CE-marked AMS ActivHeal Silicone Foam and Silicone Foam Lite dressing . The purpose of this study is primarily to collect clinical follow-up data on the AMS ActivHeal Silicone Foam and Silicone Foam Lite dressing , as CE-marking was based on equivalence. The data and conclusions obtained from this study will be used to provide clinical evidence of safety and effectiveness for the clinical evaluation process.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

160

Conditions

Wound

Interventions

Assigned interventions.OTHER

Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use, with Silicone Foam Dressing and Silicone Foam Lite Dressing. The patients will be evaluated at each dressing change over a six-week period (per Product) or until the wound is healed to extent that the use of the Silicone Foam and Silicone Foam Lite dressing is no longer indicated from the time that the patient has been recruited.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

The patient population of this evaluation will consist of patients with either a chronic or acute wound of various wound types, according to the intended use of both the AMS ActivHeal Silicone Foam and ActivHeal Silicone foam lite dressing, and they meet study eligibility criteria. Inclusion Criteria: 1. Males or females, age 18 years or above. (Females must not be pregnant and if of reproductive age should be using contraception). 2. Subjects who are able to understand and give informed consent to take part in the evaluation. 3. No local or systemic signs of infection, including new pain or increasing pain, erythema, local warmth, swelling, purulent discharge, pyrexia (in surgical wounds, typically five to seven days after surgery), delayed wound healing, abscess or malodour. 4. None to high levels of exudate Exclusion Criteria: 1. Patients who decline the invitation to take part. 2. Patients who are known to be non-compliant with medical treatment, 3. Patients who are known to be sensitive to any of the dressing components. 4. Broken/ damaged or prone to blistering peri wound skin. 5. Presence of a clinically infected wound as determined by the presence of three or more of the following clinical signs: peri wound, erythema, pain between dressing changes, malodourous wound, abundant exudate, oedema, abscess, cellulitis, purulent discharge, discolouration, friable granulation tissue which bleeds easily. 6. Patients who have a current illness or condition which may interfere with wound healing in the last 30 days which may interfere with wound healing (carcinoma, connective tissue disease, autoimmune disease or alcohol or drug abuse.) 7. Life expectancy of \<6 months.

Locations (1)

Poradnia Chorób Naczyń Obwodowych MIKOMED

Lodz, Poland

Outcomes

Primary Outcomes

Primary 1 Effectiveness of both Silicone Foam and Silicone Lite dressing will assessed in regards to the management of wound exudate.

Success will be determined by no deterioration of the wound or peri wound skin. A relative score will be used to score maceration of zero (no maceration), one (minimal maceration), two (moderate maceration), and three (excessive maceration and need to withdraw patient from study.

Time frame: After each dressing change up to 6 weeks following application of dressing

Effectiveness of both Silicone Foam and Silicone Lite dressing will assessed in regards to Wound Healing progression.

Success will be determined by no deterioration of the wound. The assessor will assess the wound size and the % tissue types within the wound.

Time frame: After each dressing change up to 6 weeks following application of dressing

Effectiveness of both Silicone Foam and Silicone Lite dressing will assessed in regards to the per wound skin conditions.

Success will be determined by no deterioration of peri wound skin. The peri wound skin will be assessed for maceration and signs of inflammation. A relative score will be used to score maceration of zero (no maceration), one (minimal maceration), two (moderate maceration), and three (excessive maceration and need to withdraw patient from study). Success will be determined that over the evaluation an increased score would represent peri wound deterioration. This will be measured using VAS value (0= no erythema, redness and skin erosion and 10 = extensive erythema, redness and skin erosion).

Time frame: After each dressing change up to 6 weeks following application of dressing

Secondary Outcomes

Effectiveness of dressing removal of both the Silicone Foam and Silicone Lite dressing will assessed.

The assessor will be required to record the pain score chosen by the patient pre removal of the dressing and record the pain score chosen by the patient during removal. Success will be determined by no increased in pain score and this will be measured using VAS value (0= no pain to 10= most pain imaginable).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.